Navigation Links
Mesa Labs Reports Higher First Quarter Earnings

LAKEWOOD, Colo., Aug. 11 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: MLAB) today reported higher earnings for the fiscal first quarter ended June 30, 2009.


  • First quarter revenues decreased less than 2% from last fiscal year
  • Operating income increased 5% over last fiscal year
  • Medical Product sales increase 12%
  • Raven Biological Indicator Product sales increase 16%

For the first quarter of fiscal 2010, net sales decreased two percent to $4,977,000 from $5,054,000 in the same quarter last year. Net income for the quarter increased one percent to $1,026,000 or $.31 per diluted share of common stock compared to $1,016,000 or $.31 per diluted share of common stock last year.

"During a time when many other companies are really struggling, we are pleased to report increased profits compared to last year," said John J. Sullivan, President and Chief Executive Officer. "This first quarter of our new fiscal year started off well and, while revenue decreased slightly compared to last year, we actually posted five percent higher orders during the quarter than the comparable period last year. Both orders and sales for our Medical and Raven lines continue to grow well, while the DataTrace line is still struggling. However, after seeing large sequential quarter-to-quarter decreases in DataTrace orders, we have recently seen a stabilization of this business, albeit at a lower level than this time last year. We are hopeful for a recovery in the DataTrace business going forward, as our customer's focus on increasing their capital equipment spending. We are also pleased with our profits this quarter. As always, we continue to closely monitor our expenses and take appropriate action to optimize the company's profit performance. While we are happy to report a five percent increase in operating profit, it did not result in a concomitant increase in net income due partially to a 79 percent decrease in the interest income on cash investments. Unless we see further weakening in the economy, in the months ahead we expect to build on the momentum established in the Medical and Raven businesses, while getting DataTrace back on a growth track."

During the first quarter of fiscal 2010, sales of the Company's medical products and services increased 12 percent compared to the prior year period. This increase was due to higher sales of dialysis meters, calibration solutions and dialysis meter service.

During the first quarter of fiscal 2010, DataTrace sales decreased 26 percent compared to the same period last year. The decrease in DataTrace sales during the quarter is the result of lower shipments of our Micropack III products and accessories, which were only partially off-set by sales of our new Micropack RF products.

Raven sales for the first quarter increased 16 percent compared to the first quarter of the prior year. The Raven biological indicator products saw sales gains in its core biological indicator strip business. Sales of Prospore and Protest products continue to increase, and we have expanded our manufacturing capacity for these products during the past fiscal year to allow the company to pursue additional opportunities for growth of these products. We also saw a substantial increase in sales of our chemical indicator products during the first quarter.

Profitability for fiscal 2010 increased slightly compared to the prior fiscal year. Gross margins decreased due to lower sales of higher margin DataTrace products and higher sales of lower margin Raven Biological Indicator products. This decrease in gross profits was off-set by reductions in operating expenses during the quarter.

Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.

This news release contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form 10-K for the year ended March 31, 2009 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.

                                FINANCIAL SUMMARY

                                                 Quarter Ended June 30
                                                 2009              2008
                                                 ----              ----
    Net Sales                                $4,977,000        $5,054,000
    Cost of Goods                             1,994,000         1,850,000
                                            -----------       -----------
    Gross Profit                              2,983,000         3,204,000
    Operating Expense                         1,375,000         1,668,000
                                            -----------       -----------
    Operating Income                          1,608,000         1,536,000
    Other (Income) & Expense                     (6,000)          (29,000)
                                            -----------       -----------
    Earnings Before Taxes                     1,614,000         1,565,000
    Income Taxes                                588,000           549,000
                                            -----------       -----------
    Net Income                               $1,026,000        $1,016,000
                                            ===========       ===========

    Earnings Per Share (Basic)               $      .32        $      .32
                                            ===========       ===========
    Earnings Per Share (Diluted)             $      .31        $      .31
                                            ===========       ===========

    Average Shares (Basic)                    3,187,000         3,170,000
                                            ===========       ===========
    Average Shares (Diluted)                  3,258,000         3,264,000
                                            ===========       ===========

    BALANCE SHEETS (Unaudited)
                                               June 30          March 31
                                                2009              2009
                                                ----              ----
    Cash and Short-Term Investments         $10,759,000        $9,111,000
    Other Current Assets                      8,719,000         9,482,000
                                            -----------       -----------
    Total Current Assets                     19,478,000        18,593,000
    Property and Equipment                    3,826,000         3,879,000
    Other Assets                              7,039,000         7,142,000
                                            -----------       -----------
    Total Assets                            $30,343,000       $29,614,000
                                            ===========       ===========

                                            -----------       -----------
    Liabilities                             $ 2,001,000       $ 2,012,000
    Stockholders' Equity                     28,342,000        27,602,000
                                            -----------       -----------

    Total Liabilities and Equity            $30,343,000       $29,614,000
                                            ===========       ===========

SOURCE Mesa Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block
2. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
3. Winner Medical Reports Third Quarter Fiscal 2009 Results
4. Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
5. DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
6. Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results
7. Cardiac Science Reports Q2 Revenue; Resumes AED Shipments
8. PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results
9. Milestone Scientific Reports 44% Increase in Revenues in First Six Months of 2009 Compared to Prior Year
10. Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
11. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... Dental professionals who ... Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) ... in Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. ...
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... The ... announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex ... Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... a double board certified facial plastic surgeon specializing in both surgical and non-surgical ... of The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study ... (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product and ... care units (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... SAN FRANCISCO , November 26, 2015 ... 1.82 billion by 2022, according to a new report by ... as Chronic Kidney Disease (CKD) which demands kidney transplantation is ... convenient and cost effective substitute for organ transplantation. --> ... 1.82 billion by 2022, according to a new report by ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Advanced Wound Care Market by Type (Dressings, Therapy ... User (In-Patient Facility, Out-Patient Facility), and Geography - Global ... --> --> The ... definition and forecast of the global advanced wound care ...
Breaking Medicine Technology: